
CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies
There are still no FDA-approved autologous chimeric antigen receptor (CAR) T-cell therapies available for solid tumors, with many constructs to date showing minimal efficacy.1 Comparatively, there are 7 commercial anti-CD19 and anti–B-cell maturation …